Book Description
Cancer Immunotherapy apart from checkpoint inhibitors is a highly personalized medicine that puts the patient's cells in the focus of drug manufacturing and promises outcomes that rarely have been seen in the history of cancer treatment. CAR-T cells can be mentioned here as the key example that has gained FDA and EMA approvals as the first living drugs for the treatment of leukemias and is now under clinical investigation for application in solid tumors as well. Improvements in cellular engineering in combination with advanced sequencing methods have made it possible to discover tumor-mutation-specific T-cell receptors that can be used to redirect effector cells toward the malignant cell pool with high specificity. This approach opens the opportunity to drug driver mutations that are occurring in a group of patients as well as to design unique patient individual treatment regimens.